Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923161 | 0.89 | MAPT (0.54) | MKNK1PTGS2MAPTRAB9AEGFR | |
| SCHEMBL924310 | 0.88 | MAPT (0.69) | MKNK1PTGS2MAPTRAB9AEGFR | |
| SCHEMBL922886 | 0.85 | MAPT (0.50) | MKNK1PTGS2MAPTRAB9AEGFR | |
| SCHEMBL923231 | 0.85 | MKNK1 (0.67) | MKNK1PTGS2MAPTRAB9AEGFR | |
| SCHEMBL923249 | 0.85 | MAPT (0.50) | MKNK1PTGS2MAPTRAB9AEGFR | |
| SCHEMBL923542 | 0.83 | PTGS2 (0.60) | MKNK1PTGS2MAPTRAB9AEGFR | |
| SCHEMBL923315 | 0.79 | PDE5A (0.41) | MKNK1MAPTEGFR | |
| SCHEMBL924123 | 0.69 | MKNK1 (0.77) | MKNK1MAPTEGFRFGFR1LMNA | |
| SCHEMBL8179134 | 0.68 | PTPN12 (0.47) | PTGS2MAPTRAB9ALMNAMAPK1 | |
| SCHEMBL922575 | 0.68 | RAB9A (0.57) | MAPTRAB9ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802849-B2 | Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-08-12 | — | — | US | claimed |
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | VICHEM CHEMIE KUTATO KFT. (HU) | 2011-01-20 | — | — | US | claimed |
| EP-2257554-A1 | TRICYCLIC BENZOÝ4,5¨THIENO-Ý2,3-D¨PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Vichem Chemie Kutató KFT (HU) | 2010-12-08 | — | — | EP | claimed |
| WO-2009104026-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | VICHEM CHEMIE KUTATÓ KFT (HU) | 2009-08-27 | — | — | WO | claimed |
| US-8802849-B2 | Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-08-12 | — | — | US | disclosed |
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | VICHEM CHEMIE KUTATO KFT. (HU) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | TYMS, TYMP, DPYD | MKNK1 2917/4885PTGS2 934/4885MAPT 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.